Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience

Tada H, Matsui S, Kawahara M, Hosoe S, Hamada C, Fukushima M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
18302648

DOI
10.1111/j.1365-2354.2007.00816.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Antineoplastic Combined Chemotherapy Protocols /adverse effects /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /mortality; Case-Control Studies; Cisplatin /administration & dosage /adverse effects; Cost-Benefit Analysis; Deoxycytidine /administration & dosage /adverse effects /analogs & derivatives; Female; Humans; Lung Neoplasms /drug therapy /mortality; Male; Middle Aged; Taxoids /administration & dosage /adverse effects; Treatment Outcome; Vinblastine /administration & dosage /adverse effects /analogs & derivatives

AccessionNumber
22008102234

Date bibliographic record published
31/03/2009